Opinion

Video

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

Author(s):

Frederick Locke, MD

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Francine Foss, MD
David C. Fisher, MD
Related Content
Leukemia
November 6th 2024

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Maurie Markman, MD, of City of Hope
October 30th 2024

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
October 29th 2024

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens